TRCT
PRVA icon

Tower Research Capital (TRC)’s Privia Health PRVA Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRVA Stock Details PRVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
11,124
+3,151
+40% +$73K 0.01% 1425
2026
Q1 		$164K Buy
7,973
+3,482
+78% +$78.5K ﹤0.01% 1776
2025
Q4 		$106K Buy
4,491
+1,987
+79% +$48.4K ﹤0.01% 1902
2025
Q3 		$62.4K Sell
2,504
-8,043
-76% -$173K ﹤0.01% 2348
2025
Q2 		$243K Buy
10,547
+9,044
+602% +$209K 0.01% 1598
2025
Q1 		$33.7K Sell
1,503
-2,175
-59% -$50.5K ﹤0.01% 2525
2024
Q4 		$71.9K Sell
3,678
-799
-18% -$15.8K ﹤0.01% 2350
2024
Q3 		$81.5K Sell
4,477
-13,334
-75% -$254K ﹤0.01% 2382
2024
Q2 		$310K Buy
17,811
+15,215
+586% +$270K 0.01% 1736
2024
Q1 		$50.9K Sell
2,596
-28,117
-92% -$594K ﹤0.01% 2268
2023
Q4 		$707K Buy
30,713
+29,571
+2,589% +$662K 0.01% 1101
2023
Q3 		$26.3K Sell
1,142
-25,483
-96% -$648K ﹤0.01% 3129
2023
Q2 		$695K Buy
26,625
+25,047
+1,587% +$662K 0.02% 749
2023
Q1 		$44K Buy
1,578
+996
+171% +$26.3K ﹤0.01% 2619
2022
Q4 		$14K Sell
582
-4,986
-90% -$139K ﹤0.01% 3529
2022
Q3 		$189K Buy
5,568
+3,894
+233% +$144K ﹤0.01% 1991
2022
Q2 		$49K Buy
1,674
+655
+64% +$16.7K ﹤0.01% 2902
2022
Q1 		$27K Buy
1,019
+528
+108% +$12.5K ﹤0.01% 3255
2021
Q4 		$13K Sell
491
-1,003
-67% -$25K ﹤0.01% 4195
2021
Q3 		$35K Buy
1,494
+949
+174% +$33.1K ﹤0.01% 3242
2021
Q2 		$24K Buy
+545
New +$20.1K ﹤0.01% 3731

Other funds holding PRVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Tower Research Capital (TRC)'s PRVA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Privia Health (PRVA) stake by 40% in Q2 2026, buying an estimated $73K and bringing the position to 11,124 shares worth $286K. The position accounts for 0.01% of the portfolio, ranked #1425.

Tower Research Capital (TRC) first reported a position in PRVA in Q2 2021 and has held it in 21 quarters since. The position peaked at $707K in Q4 2023. 301 funds tracked by Wall St. Rank hold PRVA as of Q2 2026.

  • Tower Research Capital (TRC) held 11,124 shares of Privia Health worth $286K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,151 Privia Health shares in Q2 2026, an estimated $73K.
  • Privia Health made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1425 holding.
  • Tower Research Capital (TRC) first reported a position in Privia Health in Q2 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Privia Health position peaked at $707K in Q4 2023.
  • 301 funds tracked by Wall St. Rank held Privia Health as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.